Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00747825 · ClinicalTrials.gov registry record · Phase 1
Phase I Safety and Dosimetry Study in Patients With Confirmed Metastatic Melanoma
A Phase 1 study, sponsored by Molecular Insight Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00747825: Clinical Trial Phase 1 study, sponsored by Molecular Insight Pharmaceuticals.
NCT00747825 is a Phase 1 study that was terminated before completion, run by Molecular Insight Pharmaceuticals. The registered enrollment target is 12 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00747825, a Phase 1 study, was terminated before completion, sponsored by Molecular Insight Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is an open-label, single dose study for patients 18 years of age or older with confirmed metastatic melanoma. Up to 12 patients will be enrolled and all will receive an injection of approximately 4.0 to 6.0 mCi (148-222 MBq) of 131-I-MIP-1145 administered via IV injection. The study will consist of a single dosing day followed by a 7-day assessment period and 21-day follow-up period. The total duration of the study from screening to final follow-up visit is approximately 60 days.
Interventions
- DRUG 131-I-MIP-1145
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2009-12 |
| Est. Completion | 2011-09 |
| Phase | Phase 1 |
Why NCT00747825 stopped before completion
NCT00747825 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 1 intervention - of which 131-I-MIP-1145 is the first listed.
NCT00747825 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00747825 about?
NCT00747825 is a clinical study titled "Phase I Safety and Dosimetry Study in Patients With Confirmed Metastatic Melanoma". This is an open-label, single dose study for patients 18 years of age or older with confirmed metastatic melanoma. Up to 12 patients will be enrolled and all will receive an injection of approximately 4.0 to 6.0 mCi (148-222 MBq) of 131-I-MIP-1145 administered via IV injection. The study will consis...
What is the current status of trial NCT00747825?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2009-12. Estimated completion is 2011-09.
What interventions are being tested in trial NCT00747825?
The interventions under investigation include: 131-I-MIP-1145 (DRUG).
Who is sponsoring clinical trial NCT00747825?
This trial is sponsored by Molecular Insight Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00747825's enrollment target sits among peer trials
12 1852nd of 2000 higher than 90 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia